ArticleBMJ (Clinical research ed.)1995
Transferring the costs of expensive treatments from secondary to primary care.
Article in BMJ (Clinical research ed.), 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Prevalence, incidence, indication, and choice of antidepressants in patients with and without chronic kidney disease: a matched cohort study in UK Clinical Practice Research Datalink.Pharmacoepidemiology and drug safety · 2017Article
- Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.PloS one · 2011Article
- Feasibility study of multicentre comparison of NHS hospital pharmacy computer data.British journal of clinical pharmacology · 2000Article
- The influence of hospital-based prescribers on prescribing in general practice.PharmacoEconomics · 1999Article
- Prescribing at the interface between primary and secondary care in the UK. Towards joint formularies?PharmacoEconomics · 1999Article
- General practice fundholding: progress to date.The British journal of general practice : the journal of the Royal College of General Practitioners · 1998Review
- Drug rationing in the UK National Health Service. Current status and future prospects.PharmacoEconomics · 1997Review
- Intravenous antimicrobial therapy in the community: underused, inadequately resourced, or irrelevant to health care in Britain?BMJ (Clinical research ed.) · 1996Article
- The UK pharmaceutical market. An overview.PharmacoEconomics · 1996Article
- A purchaser perspective of managing new drugs: interferon beta as a case study.BMJ (Clinical research ed.) · 1995Article
- Transferring the costs of expensive treatments. Guidelines may clarify responsibility for prescribing.BMJ (Clinical research ed.) · 1995Article
- Transferring the costs of expensive treatments from secondary to primary care.BMJ (Clinical research ed.) · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
General practitioners, especially fundholders, are becoming increasingly concerned about being asked to prescribe treatments for their patients that are outside their therapeutic experience. They are concerned about the clinical responsibility for such prescribing and the effects on their budgets. In some specialties transferring the costs of expensive treatments from secondary to primary care (cost shifting) has become partly institutionalised because of the separate sources of funding for drugs prescribed in the two sectors. With increased efforts to control the rising costs of the drugs budget and the emergence of new expensive treatments, cost shifting will be a challenge to clinicians and purchasers as they strive for rational, cost effective prescribing. A review of the funding mechanisms for drugs prescribing and of the relation between the licensing process and the decision to support the use of a treatment in primary or secondary care is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.